Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued on Monday.
Separately, JPMorgan Chase & Co. raised their target price on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research report on Tuesday, June 17th.
Check Out Our Latest Research Report on GRFS
Grifols Price Performance
Shares of NASDAQ GRFS traded up $0.39 during midday trading on Monday, hitting $9.39. The stock had a trading volume of 3,235,202 shares, compared to its average volume of 1,098,600. The company has a market capitalization of $6.46 billion, a PE ratio of 8.03, a P/E/G ratio of 0.32 and a beta of 0.55. The stock has a 50 day simple moving average of $8.32 and a 200-day simple moving average of $7.72. Grifols has a 1 year low of $6.19 and a 1 year high of $9.96. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13.
Institutional Investors Weigh In On Grifols
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc acquired a new stake in shares of Grifols in the first quarter valued at approximately $28,000. Tower Research Capital LLC TRC increased its holdings in shares of Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 6,335 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Grifols in the fourth quarter valued at approximately $75,000. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Grifols in the fourth quarter valued at approximately $77,000. Finally, Ballentine Partners LLC acquired a new stake in shares of Grifols in the first quarter valued at approximately $77,000.
About Grifols
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
See Also
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
